Efficacy and safety of low-dose tacrolimus for active rheumatoid arthritis with an inadequate response to methotrexate
0
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Background/Aims: To determine the efficacy and safety of low-dose tacrolimus in Korean rheumatoid arthritis (RA) subjects with an inadequate response to methotrexate (MTX). Methods: This was a multicenter, open-label study conducted at five Korean sites. Fifty-six patients with active RA, despite treatment for ≥ 1 month with a stable, maximally tolerated dosage of oral MTX (median dosage, 15 mg/wk), were enrolled and received 1.5 mg/day of tacrolimus as a single oral dose once per day for 16 weeks while continuing to receive MTX. All other disease-modifying anti- rheumatic drugs were discontinued, whereas stable dosages of nonsteroidal anti-inflammatory drugs and oral corticosteroids (≤ 10 mg/day of prednisone or an equivalent corticosteroid) were allowed. The primary clinical response criterion was the American College of Rheumatology’s definition of 20% improvement (ACR20) at the end of treatment. Results: The ACR20 response rate was 42.9% (24 of 56 patients) in patients who had received tacrolimus at least once. The overall ACR50 and ACR70 responses at the end of treatment for all patients were 30.4% and 10.7%, respectively. Throughout the treatment period, 37 patients experienced 71 adverse events (AEs) in total, and four patients left the study because of AEs. In addition, 15 patients in total experienced treatment-related AEs. Throughout the treatment period, two patients were reported to experience two serious AEs, and one patient left the study because of a serious AE. Conclusions: In patients whose active RA persists despite treatment with MTX, low-dose tacrolimus in combination with MTX appears to be safe and well tolerated, and provides clinical benefit.
Abstract
Background/Aims: To determine the efficacy and safety of low-dose tacrolimus in Korean rheumatoid arthritis (RA) subjects with an inadequate response to methotrexate (MTX). Methods: This was a multicenter, open-label study conducted at five Korean sites. Fifty-six patients with active RA, despite treatment for ≥ 1 month with a stable, maximally tolerated dosage of oral MTX (median dosage, 15 mg/wk), were enrolled and received 1.5 mg/day of tacrolimus as a single oral dose once per day for 16 weeks while continuing to receive MTX. All other disease-modifying anti- rheumatic drugs were discontinued, whereas stable dosages of nonsteroidal anti-inflammatory drugs and oral corticosteroids (≤ 10 mg/day of prednisone or an equivalent corticosteroid) were allowed. The primary clinical response criterion was the American College of Rheumatology’s definition of 20% improvement (ACR20) at the end of treatment. Results: The ACR20 response rate was 42.9% (24 of 56 patients) in patients who had received tacrolimus at least once. The overall ACR50 and ACR70 responses at the end of treatment for all patients were 30.4% and 10.7%, respectively. Throughout the treatment period, 37 patients experienced 71 adverse events (AEs) in total, and four patients left the study because of AEs. In addition, 15 patients in total experienced treatment-related AEs. Throughout the treatment period, two patients were reported to experience two serious AEs, and one patient left the study because of a serious AE. Conclusions: In patients whose active RA persists despite treatment with MTX, low-dose tacrolimus in combination with MTX appears to be safe and well tolerated, and provides clinical benefit.
참고문헌 (18)
- Moreland LW, "A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial", Arthritis Rheum, 64, pp.2824~2835 (2012)
- Goekoop-Ruiterman YP, "Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial", Arthritis Rheum, 52, pp.3381~3390 (2005)
- Ozminkowski RJ, "The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits", J Occup Environ Med, 48, pp.135~148 (2006)
- Kino T, "FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro", J Antibiot, 40, pp.1256~1265 (1987)
- McDiarmid SV, "Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients", Transplantation, 55, pp.1328~1332 (1993)
- Kawai S, "Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis", J Rheumatol, 33, pp.2153~2161 (2006)
- Kondo H, "Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis:a randomized, double blind, placebo controlled dose-finding study", J Rheumatol, 31, pp.243~251 (2004)
- Yocum DE, "Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial", Arthritis Rheum, 48, pp.3328~3337 (2003)
- Furst DE, "Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study", Arthritis Rheum, 46, pp.2020~2028 (2002)
- Arnett FC, "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis", Arthritis Rheum, 31, pp.315~324 (1988)
- Felson DT, "American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis", Arthritis Rheum, 38, pp.727~735 (1995)
- Kawai S, "Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patients", Rheumatology, 45, pp.441~444 (2006)
- Yocum DE, "Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience", Rheumatology, 43, pp.992~999 (2004)
- Kremer JM, "Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study", Arthritis Rheum, 48, pp.2763~2768 (2003)
- Gerards AH, "Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial", Ann Rheum Dis, 62, pp.291~296 (2003)
- Tugwell P, "Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis", Lancet, 335, pp.1051~1055 (1990)
- Smolen JS, "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs", Ann Rheum Dis, 69, pp.964~975 (2010)
- Visser K, "Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative", Ann Rheum Dis, 68, pp.1086~1093 (2009)